219 related articles for article (PubMed ID: 31755702)
41. Mercaptoacetamide: A promising zinc-binding group for the discovery of selective histone deacetylase 6 inhibitors.
Tavares MT; Kozikowski AP; Shen S
Eur J Med Chem; 2021 Jan; 209():112887. PubMed ID: 33035922
[TBL] [Abstract][Full Text] [Related]
42. Curriculum vitae of HDAC6 in solid tumors.
Zheng YC; Kang HQ; Wang B; Zhu YZ; Mamun MAA; Zhao LF; Nie HQ; Liu Y; Zhao LJ; Zhang XN; Gao MM; Jiang DD; Liu HM; Gao Y
Int J Biol Macromol; 2023 Mar; 230():123219. PubMed ID: 36642357
[TBL] [Abstract][Full Text] [Related]
43. Structure-based design generated novel hydroxamic acid based preferential HDAC6 lead inhibitor with on-target cytotoxic activity against primary choroid plexus carcinoma.
Kassab SE; Mowafy S; Alserw AM; Seliem JA; El-Naggar SM; Omar NN; Awad MM
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1062-1077. PubMed ID: 31072216
[TBL] [Abstract][Full Text] [Related]
44. Tetrahydroquinoline-Capped Histone Deacetylase 6 Inhibitor SW-101 Ameliorates Pathological Phenotypes in a Charcot-Marie-Tooth Type 2A Mouse Model.
Shen S; Picci C; Ustinova K; Benoy V; Kutil Z; Zhang G; Tavares MT; Pavlíček J; Zimprich CA; Robers MB; Van Den Bosch L; Bařinka C; Langley B; Kozikowski AP
J Med Chem; 2021 Apr; 64(8):4810-4840. PubMed ID: 33830764
[TBL] [Abstract][Full Text] [Related]
45. Expression and Crystallization of HDAC6 Tandem Catalytic Domains.
Langousis G; Sanchez J; Kempf G; Matthias P
Methods Mol Biol; 2023; 2589():467-480. PubMed ID: 36255643
[TBL] [Abstract][Full Text] [Related]
46. How Does Chirality Determine the Selective Inhibition of Histone Deacetylase 6? A Lesson from Trichostatin A Enantiomers Based on Molecular Dynamics.
Zhang Y; Ying JB; Hong JJ; Li FC; Fu TT; Yang FY; Zheng GX; Yao XJ; Lou Y; Qiu Y; Xue WW; Zhu F
ACS Chem Neurosci; 2019 May; 10(5):2467-2480. PubMed ID: 30784262
[TBL] [Abstract][Full Text] [Related]
47. Groebke Blackburn Bienaymé-mediated multi-component synthesis of selective HDAC6 inhibitors with anti-inflammatory properties.
Kraft FB; Enns J; Honin I; Engelhardt J; Schöler A; Smith ST; Meiler J; Schäker-Hübner L; Weindl G; Hansen FK
Bioorg Chem; 2024 Feb; 143():107072. PubMed ID: 38185013
[TBL] [Abstract][Full Text] [Related]
48. Pharmacophore-based virtual screening for identification of potential selective inhibitors of human histone deacetylase 6.
Uba AI; Yelekçi K
Comput Biol Chem; 2018 Dec; 77():318-330. PubMed ID: 30463049
[TBL] [Abstract][Full Text] [Related]
49. Histone deacetylase 6 inhibitor tubastatin A attenuates angiotensin II-induced hypertension by preventing cystathionine γ-lyase protein degradation.
Chi Z; Byeon HE; Seo E; Nguyen QT; Lee W; Jeong Y; Choi J; Pandey D; Berkowitz DE; Kim JH; Lee SY
Pharmacol Res; 2019 Aug; 146():104281. PubMed ID: 31125601
[TBL] [Abstract][Full Text] [Related]
50. Combined Ligand and Fragment-based Drug Design of Selective Histone Deacetylase - 6 Inhibitors.
Ruzic D; Petkovic M; Agbaba D; Ganesan A; Nikolic K
Mol Inform; 2019 May; 38(5):e1800083. PubMed ID: 30632697
[TBL] [Abstract][Full Text] [Related]
51. A Computational Approach to Investigate the HDAC6 and HDAC10 Binding Propensity of Psidium guajava-derived Compounds as Potential Anticancer Agents.
Adewole KE; Ishola AA
Curr Drug Discov Technol; 2021; 18(3):423-436. PubMed ID: 32357815
[TBL] [Abstract][Full Text] [Related]
52. Novel Selective Histone Deacetylase 6 (HDAC6) Inhibitors: A Patent Review (2016-2019).
He X; Li Z; Zhuo XT; Hui Z; Xie T; Ye XY
Recent Pat Anticancer Drug Discov; 2020; 15(1):32-48. PubMed ID: 32065106
[TBL] [Abstract][Full Text] [Related]
53. Inhibition of histone deacetylase 6 destabilizes ERK phosphorylation and suppresses cancer proliferation via modulation of the tubulin acetylation-GRP78 interaction.
Wattanathamsan O; Chantaravisoot N; Wongkongkathep P; Kungsukool S; Chetprayoon P; Chanvorachote P; Vinayanuwattikun C; Pongrakhananon V
J Biomed Sci; 2023 Jan; 30(1):4. PubMed ID: 36639650
[TBL] [Abstract][Full Text] [Related]
54. Histone deacetylase 6 in health and disease.
Seidel C; Schnekenburger M; Dicato M; Diederich M
Epigenomics; 2015; 7(1):103-18. PubMed ID: 25687470
[TBL] [Abstract][Full Text] [Related]
55. Inhibition of HDAC6 activity through interaction with RanBPM and its associated CTLH complex.
Salemi LM; Maitland MER; Yefet ER; Schild-Poulter C
BMC Cancer; 2017 Jul; 17(1):460. PubMed ID: 28668087
[TBL] [Abstract][Full Text] [Related]
56. Design and biological evaluation of tetrahydro-β-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors.
Leonhardt M; Sellmer A; Krämer OH; Dove S; Elz S; Kraus B; Beyer M; Mahboobi S
Eur J Med Chem; 2018 May; 152():329-357. PubMed ID: 29738953
[TBL] [Abstract][Full Text] [Related]
57. Inhibition of HDAC6 increases acetylation of peroxiredoxin1/2 and ameliorates 6-OHDA induced dopaminergic injury.
Jian W; Wei X; Chen L; Wang Z; Sun Y; Zhu S; Lou H; Yan S; Li X; Zhou J; Zhang B
Neurosci Lett; 2017 Sep; 658():114-120. PubMed ID: 28823893
[TBL] [Abstract][Full Text] [Related]
58. Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo.
Ojha R; Nepali K; Chen CH; Chuang KH; Wu TY; Lin TE; Hsu KC; Chao MW; Lai MJ; Lin MH; Huang HL; Chang CD; Pan SL; Chen MC; Liou JP
Eur J Med Chem; 2020 Mar; 190():112086. PubMed ID: 32058238
[TBL] [Abstract][Full Text] [Related]
59. Discovery of a fluorescent probe with HDAC6 selective inhibition.
Zhang Y; Yan J; Yao TP
Eur J Med Chem; 2017 Dec; 141():596-602. PubMed ID: 29102179
[TBL] [Abstract][Full Text] [Related]
60. A patent review of histone deacetylase 6 inhibitors in neurodegenerative diseases (2014-2019).
Shen S; Kozikowski AP
Expert Opin Ther Pat; 2020 Feb; 30(2):121-136. PubMed ID: 31865813
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
